Infectious Diseases

Riyadh, Saudi Arabia

Infectious Diseases

Riyadh, Saudi Arabia
SEARCH FILTERS
Time filter
Source Type

News Article | May 10, 2017
Site: globenewswire.com

NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the appointment of Dr. Thomas Lodise, Dr. Thomas Holland and Dr. William O’Riordan to the Clinical Advisory Board. The three new advisory board members are medical and scientific leaders in their fields: Thomas Lodise, Pharm.D., Ph.D. is a Professor at Albany College of Pharmacy and Health Sciences, Albany, New York and an infectious diseases clinical pharmacy specialist at the Stratton VA Medical Center, Albany, New York. His specific research objectives are to develop “personalized” patient care strategies that improve outcomes; reduce the likelihood of drug-induced toxicities; minimize the emergence of antibiotic resistant infections; and reduce healthcare costs.  He has published over 110 peer-reviewed articles and is an editorial board member for Antimicrobial Agents and Chemotherapy, Pharmacotherapy, and Diagnostic Microbiology and Infectious Diseases.  He is the current chair of the PK Special Emphasis Panel for the Antibacterial Resistance Leadership Group (ARLG), an initiative funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Thomas L. Holland, M.D., MSc-GH is an Assistant Professor at Duke University School of Medicine. Board certified in infectious disease, Dr. Holland has held a number of clinical positions at Duke University School of Medicine and is currently Assistant Professor in the Department of Infectious Diseases. With over 30 publications, Dr. Holland is an expert in antibacterial resistance with a focus on Gram-positive bacteria and is a member of ARLG. William D. O’Riordan, M.D. is the founder and CEO of eStudy Sites, one of the pre-eminent networks of clinical trial sites in the U.S. He is certified with the American Board of Emergency Medicine and is the lead investigator at the Chula Vista Research Site in California.  Dr. O’Riordan has held a number of clinical positions at the UCLA (University of California, Los Angeles) Medical Center and works at the Department of Emergency Medicine at the Sharp Chula Vista Medical Center. As a clinical trial investigator at the eStudy Site at the Chula Vista Research Site, he has overseen numerous clinical trials with antibacterial agents at all stages of clinical development. Dr. David Huang, CMO of Motif Bio, commented: “We are delighted to welcome these three outstanding scientific leaders to our Clinical Advisory Board. Each of them brings specific expertise that will be invaluable as we develop and prepare to commercialize iclaprim for patients with serious and life-threatening infections.” Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017. This press release contains forward-looking statements. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio’s product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio’s product candidates, (iii) Motif Bio’s ability to successfully commercialize its product candidates, (iv) Motif Bio’s ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio’s commercialization, marketing and manufacturing capabilities and strategy, (vi) Motif Bio’s expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio’s product candidates, (viii) Motif Bio’s ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bio’s estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled “Risk Factors” in Motif Bio plc’s Annual Report on Form 20-F filed with the SEC on May 1, 2017, which is available on the SEC’s web site, www.sec.gov. Motif Bio plc undertakes no obligation to update or revise any forward-looking statements.


— The IVD market in BRIC is expected to reach USD 15.71 billion by 2022 from USD 10.60 billion in 2017, at a CAGR of 8.2%. The key factors driving the growth of the market are growing patient awareness of personalized medicine, increasing prevalence of lifestyle and chronic diseases, growth in the number of private diagnostic centers, and improving healthcare system in emerging countries. However, market growth is restrained by the lack of reimbursement and the slow growth of the economy in some emerging countries. Browse 138 market data tables and 69 figures spread through 278 pages and in-depth TOC on "BRIC IVD Market by Product & Service (Instruments, Reagents, Software), Technology (Immunoassay, Hematology, Microbiology), Application (Diabetes, Cardiology, Infectious Diseases), Country (Brazil, Russia, India, China) - Forecast to 2022" In this report, the market is segmented by product & service, technology, application, end user, and country. Based on technology, the market is broadly segmented into immunoassays/immunochemistry, clinical chemistry, molecular diagnostics, hematology, clinical microbiology, coagulation & hemostasis, and other technologies. The molecular diagnostics segment is estimated to register the highest CAGR during the forecast period of 2017 to 2022. The rising prevalence of infectious diseases, cancer, and various genetic disorders; growing demand for blood screening; and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing is expected to drive the growth of the market during the forecast period. Based on application, the market is segmented into diabetes, infectious diseases, oncology/cancer, cardiology, HIV/AIDS, autoimmune diseases, nephrology, drug testing/pharmacogenomics, and others. The infectious diseases segment accounted for the largest share of the market in 2016, owing to the rising incidence of tuberculosis (TB), hepatitis, and hospital-acquired infections. Inquire for More info about IVD market Research Report At: https://goo.gl/wr3xT2 Geographically, China dominated the IVD market in BRIC in 2016. The large share of this country can be attributed to rising healthcare expenditure, increasing acceptance of personalized medicine, and increasing awareness towards technologically advanced products in this country. China is also expected to register the highest CAGR, due to the growth in research activities and increasing investments by leading players and government agencies in the country. Major players in the IVD market in BRIC and other emerging countries are Roche Diagnostics (Switzerland), Abbott Laboratories Inc. (U.S.), Siemens Healthineers (Germany), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux (France), Becton, Dickinson and Company (U.S.), Johnson & Johnson (U.S.), Ortho-Clinical Diagnostics, Inc. (U.S.), QIAGEN N.V. (Germany), and Diasorin S.P.A. (Italy). • Detailed insights on all the submarkets, based on technology (immunoassays/immunochemistry, clinical chemistry, molecular diagnostics, hematology, clinical microbiology, coagulation & hemostasis, and other technologies), this can help market players to identify high growth segments in the IVD market in BRIC and other emerging countries • The report provides information on BRIC and other emerging countries such as Mexico, Turkey, Chile, Argentina, Colombia, South Korea, Indonesia, Malaysia, Thailand, and Saudi Arabia in this market. This can help the company to assess the competition across emerging countries in a better manner. • The report also provides information on key players in this market and their growth strategies and recent developments. This can help the company to assess the competition across BRIC and other emerging countries in a better manner. • Key insights and market sizing for the different end users of the IVD market namely, hospital-based laboratories, clinical/reference laboratories, academic institutes, point-of-care testing, patient self-testing, and other end users. • BRIC and other emerging country-wise market size and forecast for all the subsegments. The market size numbers provided in the report will also enable market players to identify key geographic markets, and thereby strategize their marketing efforts to achieve sustainable revenue growth in the coming years. • It provides key insights on market dynamics, such as drivers, restraints, opportunities, and challenges for this market. The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies for increasing their market shares. This report provides insights on the following pointers: • Market Penetration: Comprehensive information on the product portfolios offered by top players in the IVD market. The report analyzes the market by product type across the BRIC and other emerging countries • Product Development/Innovation: Detailed insights on upcoming trends, R&D activities, and product launches in the IVD market in BRIC and other emerging countries • Market Development: Comprehensive information on lucrative emerging markets, based on products & services, technology, application, end user, and country • Market Diversification: Exhaustive information about new products, growing countries, recent developments, and investments in the IVD market in BRIC and other emerging countries • Competitive Assessment: Growth strategies, products, distribution networks, and manufacturing capabilities of leading players in the IVD market in BRIC and other emerging countries Order a copy of IVD Market in BRIC by Product & Service (Instruments, Reagents, Software), Technology (Immunoassay, Hematology, Microbiology), Application (Diabetes, Cardiology, Infectious Diseases), Country (Brazil, Russia, India, China) - Forecast to 2022 Research Report At: http://www.rnrmarketresearch.com/contacts/purchase?rname=1001541 ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more. For more information, please visit http://www.rnrmarketresearch.com/ivd-market-in-bric-by-product-service-instruments-reagents-software-technology-immunoassay-hematology-microbiology-application-diabetes-cardiology-infectious-diseases-country-brazil-russia-india-st-to-2022-market-report.html


The global immunohistochemistry (IHC) market is estimated to reach a value of USD 3.1 billion by 2025 The rising prevalence of cancer and increasing healthcare expenses driven by expanding aging population base are recognized to be the most influential factors driving the growth of the immunohistochemistry market. Furthermore, the rapid growth of biotech industry highlighted by increase in growth and revenue coupled with increase in stock market capitalization will nurture the growth. Cancer has high morbidity and mortality risk associated with them. The diagnosis of the disease is majorly dependent on the stage of the disease at admission. This has led to the high demand of immunohistochemistry products. IHC staining process is performed on cancer tissues to reveal the presence of HER2 receptors and/or hormone receptors on their surface. This information plays a vital role in planning the treatment for the disease, creating a demand for immunohistochemistry products. In addition, the rising popularity of targeted immunotherapy and biologic therapy for anticancer drug development and the increasing approvals of the same by the FDA to treat specific types of cancer are expected to benefit the growth in the long run. Other important factors driving growth include the alarming rise in healthcare spending and the shift in focus on value-based healthcare solutions. In 2015, the U.S. healthcare spending witnessed an increase of 5.8% to reach a value of USD 3.2 trillion. To curb the issue and establish a more value-based healthcare delivery, hospitals and care facilities are adopting a more specific and targeted therapy for better outcomes. Key Topics Covered: 1. Methodology and Scope 2. Executive Summary 3. Immunohistochemistry Market Variables, Trends & Scope 3.1. Market Segmentation & Scope 3.2. Immunohistochemistry: Market Dynamics 3.2.1. Market driver analysis 3.2.2. Market restraint analysis 3.3. Key Opportunities Prioritized 3.3.1. Key opportunities prioritized, by product 3.3.2. Key opportunities prioritized, by application 3.3.3. Key opportunities prioritized, by end-use 3.4. Immunohistochemistry - SWOT Analysis, By Factor (Political & legal, economic and technological) 4. Immunohistochemistry: Product Estimates & Trend Analysis 4.1. Immunohistochemistry Market: Product Movement Analysis 4.2. Antibodies 4.2.2. Primary Antibodies 4.2.3. Secondary Antibodies 4.3. Reagents 4.3.2. Histological Stains 4.3.3. Blocking Sera and Reagents 4.3.4. Chromogenic Substrates  4.3.5. Fixation Reagents 4.3.6. Stabilizers 4.3.7. Organic Solvents 4.3.8. Proteolytic Enzymes 4.3.9. Diluents 4.4. Equipment 4.4.2. Slide Staining Systems 4.4.3. Tissue Microarrays 4.4.4. Tissue Processing Systems 4.4.5. Slide Scanners 4.4.6. Others 4.5. Kits 5. Immunohistochemistry: Application Estimates & Trend Analysis 5.1. Immunohistochemistry Market: Application Movement Analysis 5.2. Diagnostics 5.2.2. Cancer 5.2.3. Infectious Diseases 5.2.4. Cardiovascular diseases 5.2.5. Autoimmune Diseases 5.2.6. Diabetes Mellitus 5.2.7. Nephrological Diseases 5.3. Drug Testing  6. Immunohistochemistry: End-Use Estimates & Trend Analysis 6.1. Immunohistochemistry Market: Application Movement Analysis 6.2. Hospitals and Diagnostic Laboratories 6.3. Research Institutes 6.4. Others 7. Immunohistochemistry: Regional Estimates & Trend Analysis, by Product, Application, and End-use 8. Competitive Landscape For more information about this report visit http://www.researchandmarkets.com/research/gkgmnp/immunohistochemist Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/31-billion-immunohistochemistry-ihc-market-analysis-and-forecast-segments-2014-2025-by-product-application--end-uses---research-and-markets-300455123.html


DUBLIN, May 9, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Point of Care Testing Market, by Product (Glucometers, BGE Analyzers, Pregnancy Tests, Infectious Diseases, etc.), Outlook 2022" report to their offering. It is predicted that by...


News Article | May 9, 2017
Site: www.businesswire.com

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) (“Navidea” or “the Company”), a company focused on the development and commercialization of precision immunodiagnostic agents, today announced its financial results for the first quarter of 2017. Navidea reported total revenue (excluding discontinued operations) for the quarter of $580,000. Net income attributable to common stockholders was $85.6 million. “Navidea ended the first quarter with strong momentum built upon the strategic plan developed over the past two quarters. Our strategy is designed to maximize the value of our proprietary macrophage-targeting technology by developing and out-licensing promising imaging and therapeutic products,” said Michael Goldberg, M.D., Navidea’s President and CEO. Dr. Goldberg continued, “Our completed sale of the North American rights to Lymphoseek® to Cardinal Health 414, LLC ensures that our focus remains on product development going forward. We are confident that our Manocept platform, properly developed, will yield both diagnostics and therapeutics that can generate significant value for our stockholders.” The flexible and versatile Manocept platform acts as an engine for the design of targeted imaging molecules applicable to a range of diagnostic modalities, including single photon emission computed tomography (“SPECT”), positron emission tomography (“PET”), gamma-scanning (both imaging and topical) and intra-operative and/or optical-fluorescence detection. We have active clinical diagnostic programs in cardiovascular disease, rheumatoid arthritis, Kaposi’s sarcoma and colorectal cancer, diseases representing both major macrophage activation states. Cardiovascular Disease – The results of a study to evaluate diagnostic imaging of emerging atherosclerosis plaque with Tc 99m tilmanocept were published in early release in the Journal of Infectious Diseases on January 16, 2017, confirming that the Tc 99m tilmanocept product can both quantitatively and qualitatively target non-calcified plaque in the aortic arch. Colorectal Cancer and Synchronous Liver Metastases – During the first quarter of 2017, we initiated an imaging study in subjects with colorectal cancer and liver metastases via intravenous administration of Tc 99m tilmanocept. Navidea’s majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”), has developed processes for producing the first two therapeutic Manocept immunoconstructs consisting of a therapeutic molecule conjugated to moieties targeting CD206+ macrophages: In the first quarter of 2017, MT completed its third vivo study dosing either MT-1002 or MT-2002 in a well-established mouse model of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis and liver fibrosis, in which both compounds significantly reduced key disease parameters. Also in the first quarter of 2017, we completed a series of predictive in vitro screening tests of the MT-1002 and MT-2002 therapeutic conjugates against the Zika and Dengue viruses and against Leishmaniosis. These evaluations were positive and MT will begin in vivo testing in the second or third quarter of 2017. Our consolidated balance sheets and statements of operations have been reclassified, as required by current accounting standards, for all periods presented to reflect the line of business sold to Cardinal Health 414 as a discontinued operation. Accordingly, this discussion focuses on describing results of our operations as if we had not operated the discontinued operation during the periods being disclosed. We recorded a net gain on the sale to Cardinal Health 414 of $88.7 million for the first quarter of 2017, including $16.5 in guaranteed consideration, which was discounted to the present value of future cash flows. The proceeds were offset by $3.3 million in estimated fair value of warrants issued to Cardinal Health 414, $2.0 million in legal and other fees related to the sale, $800,000 in net balance sheet dispositions and write-offs, and $4.6 million in estimated taxes. Total revenues for the quarter ended March 31, 2017 were $580,000 compared to $948,000 in the first quarter of last year. Total operating expenses for the first quarter of 2017 were $3.7 million, compared to $4.7 million in the first quarter of last year. Research and development expenses for the first quarter of 2017 were $705,000, compared to $2.1 million in the first quarter of last year. The net decrease from 2016 to 2017 was primarily a result of decreases in NAV4694, Tc 99m tilmanocept and NAV5001 development costs, offset by increases in Manocept and therapeutics development costs, coupled with decreased compensation and related support costs. Selling, general, and administrative expenses for the first quarter of 2017 were $3.0 million, compared to $2.6 million in the first quarter of last year. The net increase was primarily due to increased legal and professional services, offset by decreased investor relations services, compensation and related support costs. Navidea’s net income attributable to common stockholders for the quarter ended March 31, 2017 was $85.6 million, or $0.53 per share (basic), compared to a net loss of $3.7 million, or $0.02 per share, for the same period in 2016. Navidea ended the quarter with $13.4 million in cash. Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast reply is expected to be available on our investor website, http://ir.navidea.com, approximately two to four hours after the live event. Event: Navidea Q1 2017 Financial Results Conference Call Date/Time: Wednesday, May 10, 2017 at 8:00 a.m. ET Webcast Link: http://edge.media-server.com/m/p/zjm948a2/lan/en Dial-In Number (US): (855) 897-5884 Dial-In Number (International): (720) 634-2940 Conference ID: 20720582 Replay: A webcast replay will be available on the Investor Relations section of our website at http://ir.navidea.com following the event Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its ManoceptTM platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.


It is predicted that by 2022 the global Point of Care Testing market will reach U$$ 30 Billion. The Point-of-care tests have immense potential to improve global health and to eventually reduce public and national spending on health. These devices have now found applications in a large number of medical conditions. Due to its increased usage in the field of critical care settings to deliver decentralized, patient-centric health care to the patients, the projections for the global Point of Care Testing market is expected to witness a rapid growth. The report Global Point of Care Testing Market, by Product (Glucometers, BGE Analyzers, Pregnancy Tests, Infectious Diseases, etc.), Outlook 2022 provides a detailed analysis of the current and future market scenario of the global market with a brief outlook of the IVD industry. The global Point of Care Testing market has been segmented on the basis of type of product. The major types of Point of Care Testing present in the market include glucose monitoring kits, blood gas and electrolyte analysers, pregnancy & fertility testing kits, cardiac markers, infectious diseases testing kits, and coagulation monitoring kits amongst others. According to the report, glucose monitoring kits is estimated to account for the largest share in 2016 due rising prevalence of diabetes & technological advancements in self-monitoring of blood glucose. Based on geography, the report divides the market into North America, Europe, Asia-Pacific, and Rest of the World. In 2016, North America is estimated to account for the largest share. The last section of the report discusses about the prominent players in global Point of Care Testing market. Market share analysis of these players is also provided in the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors. 3.2 What is In Vitro Diagnostics? 5.1.2 Rising Use of Home Based Point of Care Diagnostics For more information about this report visit Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-30-billion-point-of-care-testing-glucometers-bge-analyzers-pregnancy-tests-infectious-diseases-market-outlook-2022---research-and-markets-300454249.html


News Article | May 10, 2017
Site: globenewswire.com

NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the appointment of Dr. Thomas Lodise, Dr. Thomas Holland and Dr. William O’Riordan to the Clinical Advisory Board. The three new advisory board members are medical and scientific leaders in their fields: Thomas Lodise, Pharm.D., Ph.D. is a Professor at Albany College of Pharmacy and Health Sciences, Albany, New York and an infectious diseases clinical pharmacy specialist at the Stratton VA Medical Center, Albany, New York. His specific research objectives are to develop “personalized” patient care strategies that improve outcomes; reduce the likelihood of drug-induced toxicities; minimize the emergence of antibiotic resistant infections; and reduce healthcare costs.  He has published over 110 peer-reviewed articles and is an editorial board member for Antimicrobial Agents and Chemotherapy, Pharmacotherapy, and Diagnostic Microbiology and Infectious Diseases.  He is the current chair of the PK Special Emphasis Panel for the Antibacterial Resistance Leadership Group (ARLG), an initiative funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Thomas L. Holland, M.D., MSc-GH is an Assistant Professor at Duke University School of Medicine. Board certified in infectious disease, Dr. Holland has held a number of clinical positions at Duke University School of Medicine and is currently Assistant Professor in the Department of Infectious Diseases. With over 30 publications, Dr. Holland is an expert in antibacterial resistance with a focus on Gram-positive bacteria and is a member of ARLG. William D. O’Riordan, M.D. is the founder and CEO of eStudy Sites, one of the pre-eminent networks of clinical trial sites in the U.S. He is certified with the American Board of Emergency Medicine and is the lead investigator at the Chula Vista Research Site in California.  Dr. O’Riordan has held a number of clinical positions at the UCLA (University of California, Los Angeles) Medical Center and works at the Department of Emergency Medicine at the Sharp Chula Vista Medical Center. As a clinical trial investigator at the eStudy Site at the Chula Vista Research Site, he has overseen numerous clinical trials with antibacterial agents at all stages of clinical development. Dr. David Huang, CMO of Motif Bio, commented: “We are delighted to welcome these three outstanding scientific leaders to our Clinical Advisory Board. Each of them brings specific expertise that will be invaluable as we develop and prepare to commercialize iclaprim for patients with serious and life-threatening infections.” Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017. This press release contains forward-looking statements. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio’s product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio’s product candidates, (iii) Motif Bio’s ability to successfully commercialize its product candidates, (iv) Motif Bio’s ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio’s commercialization, marketing and manufacturing capabilities and strategy, (vi) Motif Bio’s expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio’s product candidates, (viii) Motif Bio’s ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bio’s estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled “Risk Factors” in Motif Bio plc’s Annual Report on Form 20-F filed with the SEC on May 1, 2017, which is available on the SEC’s web site, www.sec.gov. Motif Bio plc undertakes no obligation to update or revise any forward-looking statements.


Antibiotics used to treat a variety of common bacterial infections are becoming more difficult to access, mostly because the drugs are less profitable for manufacturers to produce and market. Writing in a commentary in Clinical Microbiology and Infection [1], researchers say the problem is particularly acute for formulations needed to treat sick babies and children. They say doctors increasingly have to use alternative antibiotic treatments, which may have worse side-effects for patients, including encouraging the growth of drug-resistant bacteria - one of the greatest threats to public health. The lead author of the report is Céline Pulcini, Professor of Infectious Diseases at Nancy University Hospital and University of Lorraine, France, and secretary of the European Society of Clinical Microbiology and Infectious Diseases' (ESCMID) Study Group for Antibiotic Policies (ESGAP). The report was co-authored by a group of experts from different organisations, including ESCMID, Action on Antibiotic Resistance (ReAct), the International Society of Chemotherapy, the British Society for Antimicrobial Chemotherapy and the French Infectious Diseases society (SPILF). Prof. Pulcini explained: "These are drugs that have been available for many years but they are still effective for treating conditions such as skin infections, cystitis and sore throat. Some of them also have a role to play in tackling drug-resistant bacteria. "However, their patents expired many years ago and drug manufacturers may see them as less attractive prospects to register, sell and market in countries around the world." Prof. Pulcini and her colleagues say older drugs, such as penicillins, are still effective in the majority of infectious diseases and many are on the WHO's Essential Medicines List. However, they report that when these older antibiotics are not available, patients need to be treated with alternative antibiotics that in some situations might be less effective, usually cause more side-effects (including encouraging the growth of drug-resistant bacteria) and are sometimes more expensive. Some of these older drugs, for example IV fosfomycin and colistin, also have an important role to play in treating multidrug resistant bacteria. The authors found that absence of marketing of older antibiotics is primarily caused by the high costs involved in registering medicines in multiple countries. This is combined with the relatively small market for these antibiotics, which are sold as low-cost generics and for short courses of treatment. Previous research in 38 countries has shown that out of 33 older but effective antibiotics, 22 were marketed in fewer than 20 countries, and that the situation was deteriorating. Research has also revealed repeated and prolonged shortages of many antibiotics. For example, in the USA between 2001 and 2013, 148 different antibiotics were in shortage, many on multiple occasions. The authors say little is known about the situation in poorer nations but evidence suggests it is even worse. Prof. Pulcini added: "There are additional challenges for treating babies and children. With these patients, doctors often need much smaller doses and different formulations, for example a liquid medicine rather than a tablet. In many cases, no paediatric formulation is available. Bacterial infections can be particularly dangerous for premature babies. But their medical teams may have to contend with adult-sized vials when only a fraction of the dose is needed." The authors say that the situation requires intervention by groups like the World Health Organisation (WHO) and the European Commission to ensure availability of antibiotics. Prof. Pulcini said: "While it's important that we continue to look for new effective antibiotics, we must put equal effort into ensuring that patients of all ages have access to existing effective treatments. "The availability of these essential medicines must be made a priority globally. International organisations, such as the WHO, should take the lead here, working with Member States to ensure sustainable global access to all essential antibiotics, in their optimal formulation, quality and cost, to everyone everywhere. "If no action is taken we will lose these excellent and relatively cheap antibiotics that are needed on a daily basis to treat common bacterial infections worldwide. Instead, we will end up using less efficient antibiotics, leading to worse clinical outcomes for patients, and adding to the problem of antibiotic resistance."


LONDON, May 11, 2017 /PRNewswire/ -- Global Pharmerging Market: Overview This report on pharmerging market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pharmaceutical products as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global pharmerging market with respect to the leading market segments based on major products, applications and geographies. Download the full report: https://www.reportbuyer.com/product/4895309/ The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global pharmerging market and could influence the market in the near future. Market attractiveness analysis has been provided in all the sections of the report in order to explain the intensity of competition in the market across different products/materials/technologies/end-users/geographies. The competitive scenario among different market players is evaluated through market share analysis in the competition landscape section of the report. The section also includes competition matrix that analyzes the competition among some of the top global players operating in the market. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market. Global Pharmerging Market: Segmentation The global pharmerging market is divided into: by product, by economic growth levels, by distribution channel and by geography. Product type segment of pharmerging market was divided into Pharmaceuticals (Branded Prescription Drugs, Generic Drugs (Branded Generics, Unbranded Generics), and OTC Drugs) and Healthcare (Medical Devices, and Diagnostic Instruments, Others (IT and record management)). On the basis of Economic Growth Levels the market was divided as - Tier – 1, Tier – 2 and Tier – 3). On the basis of distribution channel the pharmerging market is divided as hospitals, clinics, retail pharmacies, e-commerce, and drug stores. The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn and market volume in terms of units for the period from 2016 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2016 as the base year. Geographically, the pharmerging market has been segmented into five regions: North America, Europe, Asia Pacific, Europe, Middle East & Africa (MEA), and Latin America. Each regional market for pharmerging market has been further categorized into major product, applications, material, and end-user segments considered within the scope of the study. Key country (U.S., Canada, Japan, Germany, France, U.K., Australia, Canada, China, Brazil, Mexico, India, etc.) market revenues have also been provided in different regional sections within the report. Market revenue in terms of US$ Mn and volume in terms of units for the period from 2014 to 2025 along with CAGR % from 2016 to 2025 are provided for all the regions and nations considering 2016 as the base year. Companies Mentioned in the Research Report The report profiles key manufacturers in the pharmerging market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include Abbott Laboratories, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AstraZeneca, GlaxoSmithKline plc., LUPIN, Tata Consultancy Services Limited, Sun Pharmaceutical Industries Ltd., Huadong Medicine Co., Ltd., etc. The global pharmerging Market has been segmented as follows: By Product Type Pharmaceuticals Branded Prescription Drugs Generic Drugs Branded Generics Unbranded Generics OTC Drugs Healthcare Medical Devices Diagnostic Instruments Others (IT and record management) By Indications Lifestyle Diseases Cancer and autoimmune diseases Infectious Diseases Others By Distribution Channel Hospitals Clinics Retail Pharmacies E-commerce Drug Stores By Region Europe Asia Pacific Latin America Middle East and Africa Download the full report: https://www.reportbuyer.com/product/4895309/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmerging-market-and-healthcare---global-industry-analysis-size-share-growth-trends-and-forecast-2016---2024-300456372.html


Mothers infected with malaria during pregnancy can pass more of their own cells to their baby and change the infant's risk of later infection, a new study shows. The study, from researchers at Fred Hutchinson Cancer Research Center and their colleagues, suggests that a mother's cells could directly act as part of her child's immune system, even after birth. The placenta blocks some infectious agents, but easily passes oxygen and nutrients to the baby. It also allows a unique exchange of cells between mother and child, known as "microchimerism." The research team looked at how malaria can alter the mother-child cell sharing that happens during pregnancy. It was led by Dr. Whitney Harrington, University of Washington and Seattle Children's Hospital pediatric infectious disease specialist, and Fred Hutch microchimerism researcher Dr. J. Lee Nelson. Most babies carry a very small number of foreign cells acquired from their mothers, on the order of a few maternal cells in every 100,000, but the researchers found that babies born to Tanzanian mothers infected with malaria during pregnancy and whose infections had traveled to their placentas had evidence for far more maternal cells on board at the time of their births -- on average about one percent, with a few cases even higher than 10 percent. The level of increase of mother's cells present in baby's blood was a surprise to the researchers. Harrington hypothesizes that the infection led to alterations in placental proteins that control cell trafficking, which allowed more maternal cells to enter the fetuses. Even more surprising was the lasting effect of this change. When the researchers looked at the health records of the babies, they found that those with higher levels of maternal microchimerism were twice as likely to be infected with malaria during childhood - but only half as likely to get sick from that infection, suggesting that the cells transferred from the mothers might confer some protection against the disease. Harrington said there are two possible explanations for what's going on: Either mom's immune cells are directly recognizing and acting on the malaria parasite in her child's body, or they're acting indirectly by teaching the child's immune system how to recognize and react to the pathogen. The researchers examined 53 umbilical cord blood samples from pregnant women and their babies enrolled in a previous study in Muheza, Tanzania, from 2002 to 2006. About half of the women had placental malaria, and about half of those infected women had what's called inflammatory placental malaria, in which the placenta gets very diseased and can stop functioning properly. In their study, the researchers looked for the amount of maternal DNA in the babies' umbilical cord blood. This is representative of the level of maternal microchimerism the children had at the moment they were born, Harrington said, although it's not known how long that level may persist after birth. Women with placental malaria gave birth to babies with higher-than-average maternal microchimerism, and babies born to mothers with inflammatory placental malaria had even higher average levels. In future studies, the researchers plan to explore how the maternal and infant cells interact to affect future malaria risk, whether and for how long the high levels of maternal cells persist during children's lives, and how in general a person's microchimerism status affects their susceptibility to other childhood infections. Malaria is a leading cause of death in low- and middle-income countries, especially among children. An estimated 429,000 people die every year of the infection, according to the World Health Organization, and the majority of those deaths occur in sub-Saharan Africa. Harrington is first author of the Journal of Infectious Diseases article; Nelson is last author. The study was supported by the Thrasher Research Fund; the National Institutes of Health (T32HD007233 and R01 HL117737-15); and the Intramural Research Program of the National Institute of Allergy and Infectious Diseases of the NIH. For more information on this study, please click here. At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.

Loading Infectious Diseases collaborators
Loading Infectious Diseases collaborators